Ernst & Young accounting firm
Overseas registration of Mainland Individuals control
P.O. Box 472, Harbour Place, 2nd Floor 103 South Church Street, George Town Grand Cayman KY1-1106, Cayman Islands
Head Office and Principal Place of Business
54 / F, Hopewell Centre, 183 Queen's Road East, Hong Kong
Hong Kong motherboard
Heplatinum Pharmaceutical Holdings Co., Ltd. is an investment holding company mainly engaged in the development of innovative therapies in the field of tumor immunology and immune diseases. The company's products include bartolizumab, mainly for immune thrombocytopenia, thyroid associated ophthalmopathy, myasthenia gravis, optic neuromyelitis spectrum diseases, and tenacil, mainly for dry eye diseases. In addition, the company also studies and develops tumor immunization product lines, including internally developed new-generation tumor immune assets for the treatment of immune desert, immune rejection and inflammatory tumors.
We are a clinical stage biopharmaceutical company, registered in July 2016, engaged in the research and development of differentiated antibody therapy in the field of immune and tumor diseases. We are committed to the discovery, development and commercialization of innovative antibody therapies to meet unmet patient needs.
Rich product portfolio and differentiated pipelines
We have a rich and differentiated product pipeline with more than ten potential differentiated drug candidates, four of which are under clinical development. HBM9161, HBM9036, HBM4003 and HBM7008 are our main products.
Bartoli monoclonal antibody (HBM9161)
Bartoli monoclonal antibody is a kind of all-human monoclonal antibody which selectively binds and inhibits the neonatal crystal fragment receptor ("FcRn").
It plays a key role in preventing IgG antibody degradation. High level of pathogenic IgG antibody can induce many kinds of autoimmune diseases. As the most cutting-edge clinical FcRn inhibitor developed in Greater China, Bartolizumab has the potential to become a breakthrough therapy for a variety of autoimmune diseases in Greater China. We are developing bartolizumab in Greater China with an initial focus on myasthenia gravis ("MG"), immune thrombocytopenia ("ITP"), optic neuromyelitis spectrum disease ("NMOSD"), thyroid associated ophthalmopathy ("TED"), chronic inflammatory demyelinating polyradiculoneuropathy ("CIDP") and pemphigus ("PV").
Tenalcip has developed for us a cutting-edge candidate for the treatment of moderate and severe dry eye disease ("DED"), which is in the third stage of clinical practice. The mechanism of action of teranercept is to inhibit tumor necrosis factor (TNF)-α, which can lead to eye inflammation. With the rapid growth of the use of electronic products and the problems caused by the aging society, more and more people are troubled by dry eyes in their work and life. Tenercept has the potential to win most of the market share in China's fast-growing market for dry eye drugs.
HBM4003 is a new generation of all-human anti-CTLA-4 antibody, which can be used to inhibit T lymphocyte associated antigen-4 (CTLA-4) (one of the main negative regulatory cytotoxic factors of T cell response). It is also the first internal development molecule to be generated through our HCAb platform and has advanced from the candidate drug screening phase to the clinical stage within three years. HBM4003 is the first anti-CTLA-4 heavy chain antibody in the world to enter the clinical development stage, and in the preclinical stage, it has better characteristics than the traditional anti-CTLA-4 antibody. Compared with traditional anti-CTLA-4 antibodies, HBM4003 has significantly increased T regulatory cell elimination mechanism and improved pharmacokinetics ("competition"). At the same time, by enhancing the antibody-dependent cytotoxicity ("ADCC") strategy to enhance the potential of HBM4003 selective Treg cytotoxicity, we believe that HBM4003 will be able to break the immunosuppressive barrier of anti-tumor immunotherapy in solid tumors. HBM4003 is expected to overcome the efficacy and safety bottlenecks of existing molecules and become the core product in the field of tumor immunotherapy.
HBM7008 is a bispecific antibody against tumor-associated antigen (B7H4) x4-1BB. Because it relies heavily on tumor-associated antigen-mediated cross-linking with T cell activation, it is not only effective in T cell costimulation and inhibition of tumor growth, but also expected to improve safety. HBM7008 is one of them based on our company's HBICE? The whole human bispecific antibody developed by the platform is also the only bispecific antibody against these two targets in the world. Its unique tumor expression specificity and immunomodulatory activity are expected to produce better efficacy in PD-L1-negative patients or in patients with drug resistance to PD1/PD-L1 immunotherapy drugs. With its new biological mechanism and double antibody design, we hope to avoid the risk of hepatotoxicity observed by 4-1BB in other products. As a biopharmaceutical company dedicated to the discovery and development of differentiated antibody therapy in the field of immune and tumor diseases, we have also explored and developed a number of projects, including novel and challenging monoclonal antibody projects, such as HBM1022 (CCR8), HBM1020 (B7H7, which is also a potential first of its kind for this target), HBM1007 (a CD73 targeted monoclonal antibody with dual action mechanism) and HBM9378 (a TSLP targeted monoclonal antibody). With better bioavailability), and produced in HBICE? Platform bispecific antibodies, these antibodies have novel designs and differentiated mechanisms, such as HBM7020 (BCMAxCD3).
Leading Drug Innovation and Discovery engine
HBM4003 and many other internal projects are run by our proprietary Harbour Mice? Platform development. Our Harbour Mice? Platform, can produce classic double double chain double light chain (H2L2) form and only heavy chain (HCAb) form of monoclonal antibody. H2L2 platform can quickly and massively produce typical double and light immunoglobulin chain antibodies (H2L2) with modified whole-human variable region, realizing endogenous affinity maturation and immune effect function. HCAb platform is a human antibody platform, which can produce different kinds of heavy chain-only antibodies (such as nano-antibodies, bispecific or multi-specific antibodies and CAR-T) and has good feasibility for development. With the know-how accumulated from the HCAb platform, we have independently developed HBICE? The platform, which focuses on generating differentiated bispecific antibodies against HCAb-based immune cell connectors (expected to achieve tumor elimination that cannot be achieved by combination therapy). Combined with our monoclonal B cell screening platform, our efficient antibody discovery engine effectively promotes the company's innovation and sustainable growth.
Business cooperation to maximize the value of the platform
We have the global right to use and develop platinum antibody platforms, enabling us to maximize the value of our platforms to address unmet global medical needs. We expand our business with leading academic institutions globally and select industrial partners focused on innovation and efficiency. Our business cooperation model with Platinum Antibody platform is not limited to pure technology licensing, but also includes co-discovery ╱ co-development with academic institutions or other leading innovation pioneers in the industry on the next generation of innovative therapies. The platform has been recognized by more than 50 industry and academic partners. Based on our good track record of cooperation, we believe that Platinum Antibody platform will have the potential to generate revenue and broaden the scope of our R & D work.